Mark R. Fielden

Development of a large-scale chemogenomics database to improve drug candidate selection and to understand mechanisms of chemical toxicity and action

Brigitte Ganter, Stuart Tugendreich, Cecelia I. Pearson et al. · Journal of Biotechnology · 2005 · 286 citations

Drug Target, Engineering, Predictive Toxicology +15

Induction of Cyp1a1 Is a Nonspecific Biomarker of Aryl Hydrocarbon Receptor Activation: Results of Large Scale Screening of Pharmaceuticals and Toxicants in Vivo and in Vitro

Wenyue Hu, Claudio Sorrentino, Michael S. Denison et al. · Molecular Pharmacology · 2007 · 217 citations

A Gene Expression Biomarker Provides Early Prediction and Mechanistic Assessment of Hepatic Tumor Induction by Nongenotoxic Chemicals

Mark R. Fielden, Richard Brennan, Jeremy Gollub · Toxicological Sciences · 2007 · 206 citations

Signature Profile, Engineering, Pathology +21

Comparative analysis of dioxin response elements in human, mouse and rat genomic sequences

Yanni Sun, Darrell R. Boverhof, Lyle D. Burgoon et al. · Nucleic Acids Research · 2004 · 205 citations · Full text

Examination of the estrogenicity of 2,4,6,2',6'-pentachlorobiphenyl (PCB 104), its hydroxylated metabolite 2,4,6,2',6'-pentachloro-4-biphenylol (HO-PCB 104), and a further chlorinated derivative, 2,4,6,2',4',6'-hexachlorobiphenyl (PCB 155).

Mark R. Fielden, I Chen, Brock Chittim et al. · Environmental Health Perspectives · 1997 · 114 citations · Full text

Endocrine Disruptors, Biochemistry, Pcb 155 +14